Britain and America have forged a important bilateral deal that will maintain no levies on British pharmaceutical exports going into the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to boost funding on drugs through the National Health Service (NHS). This move guarantees that import taxes on these key goods will stay at zero for a period of three years.
This agreement follows earlier threats to hike tariffs on patented drug imports, with figures discussed as high as double the cost.
"This agreement with the Britain reinforces the worldwide climate for new treatments and establishes much-needed equity to American-British medicine commerce," an announcement said.
Trade Importance
Medicines represent one of the UK's most significant export categories to the United States, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months leading up to last September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This value represented 17.4% of total UK exports in that span.
"This guarantee safeguards work, stimulates funding and facilitates the UK to emerge as a global hub for life sciences," a minister commented.
Key NHS Changes
The agreement involves several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Last year, refunds topped twenty percent.
Recent Tensions
This agreement follows a ongoing row between the sector and the British authorities over spending levels and NHS adoption.
These tensions were heightened by claims that American customers were charged several times more for the identical medicines than consumers in the other developed nations.
In recent months, several large drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
The Science Minister stated that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had shrunk as a share of its resources over the previous ten-year period.
